Gram-Positive Bacterial Infections Clinical Trial
Official title:
Time To Efficacy and Onset Of Action Of Linezolid In Skin and Soft Tissue Infections
Verified date | May 2011 |
Source | Pfizer |
Contact | n/a |
Is FDA regulated | No |
Health authority | Germany: Federal Institute for Drugs and Medical Devices |
Study type | Interventional |
To assess the onset of action of linezolid
Status | Completed |
Enrollment | 118 |
Est. completion date | June 2005 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - suspected grampositive infection - fever > 38 C Exclusion Criteria: - Infections to be treated successfully by surgical procedures |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Pfizer |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time to defervescence | |||
Secondary | Reduction of CRP levels Reduction of leucocyte count |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01412801 -
Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings
|
Phase 2 | |
Terminated |
NCT00108433 -
Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections
|
Phase 3 | |
Completed |
NCT00501150 -
Oral Antibiotic Treatment at Home Instead of Intravenous Treatment in Hospital for Resistant Gram Positive Infections
|
N/A | |
Not yet recruiting |
NCT06444802 -
Model-informed Precision Dosing for Linezolid
|
Phase 3 | |
Terminated |
NCT00529282 -
A Study of Ceftobiprole in Patients With Fever and Neutropenia.
|
Phase 3 | |
Completed |
NCT00079976 -
Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA)
|
Phase 3 | |
Terminated |
NCT00835783 -
Validation Study of Combined Positron Emission Tomography/Computer Tomography to Diagnose Infection and Inflammation
|
N/A | |
Completed |
NCT00081744 -
Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects
|
Phase 3 | |
Completed |
NCT03747497 -
Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection
|
Phase 2 | |
Active, not recruiting |
NCT04911270 -
Clinical Decision Support Tool for Vancomycin Dosing in Children
|
N/A | |
Completed |
NCT02750761 -
A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013)
|
Phase 1 | |
Completed |
NCT00406198 -
Impact of Continuous Venovenous Haemofiltration on Organ Failure During the Early Phase of Severe Sepsis
|
Phase 4 | |
Completed |
NCT03560440 -
Evaluation of the Dosing Regimen of Vancomycin in Pediatric Patients
|
||
Terminated |
NCT00240747 -
Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients
|
Phase 3 | |
Not yet recruiting |
NCT04917380 -
The Clinical Character,Risk and Prognosis of Post-neurosurgical Intracranial Infection With Different Pathogens.
|
||
Completed |
NCT00736554 -
What is the Prevalence of Methicillin-Resistant Staphylococcus Aureus in Skin and Soft Tissue Infections Presenting to the Emergency Departments of a Canadian Academic Health Care Center?
|
N/A | |
Completed |
NCT03361163 -
Controlled Human Infection for Vaccination Against Streptococcus Pyogenes
|
Phase 1 | |
Completed |
NCT00167960 -
Study Evaluating Vancomycin-Resistant Enterococci in a Hematology Unit
|
Phase 4 | |
Completed |
NCT00874367 -
Early-Onset Sepsis Surveillance Study
|
N/A | |
Completed |
NCT00167999 -
Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units
|
Phase 4 |